{
  "source": "PA-Notification-Epclusa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1197-9\nProgram Prior Authorization/Notification\nMedication Epclusa® (sofosbuvir/velpatasvir)\nP&T Approval Date 8/2016, 8/2017, 8/2018, 8/2019, 8/2020, 8/2021, 8/2022, 8/2023,\n8/2024\nEffective Date 11/1/2024\n1. Background:\nEpclusa (sofosbuvir/velpatasvir) is a fixed-dose combination of sofosbuvir, a hepatitis C virus\n(HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A\ninhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and\nolder with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection:\n• without cirrhosis or with compensated cirrhosis\n• with decompensated cirrhosis for use in combination with ribavirin\n2. Coverage Criteriaa:\nA. For the treatment of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection, Epclusa will be\napproved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection\n-AND-\n2. Patient is not receiving Epclusa in combination with another HCV direct acting antiviral\nagent [e.g., Sovaldi (sofosbuvir)]\n-AND-\n3. One of the following:\na. Patient does not have decompensated liver disease (e.g., Child-Pugh Class B or C)\n-OR-\nb. Both of the following:\n(1) Patient has decompensated liver disease (e.g., Child-Pugh Class B or C)\n-AND-\n(2) Used in combination with ribavirin\nAuthorization will be issued for 12 weeks.\n© 2024 UnitedHealthcare Services Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic c",
    "uthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place\n• Medical necessity may be in place.\n4. References:\n1. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2022.\nProgram Prior Authorization/Notification – Epclusa (sofosbuvir/velpatasvir)\nChange Control\nDate Change\n8/2016 New program.\n8/2017 Annual review with no changes to coverage criteria. Updated\nreference.\n8/2018 Annual review with no changes to coverage criteria. Updated\nreference.\n8/2019 Annual review with no changes to coverage criteria.\n8/2020 Annual review with no changes to coverage criteria. Updated\nreference.\n8/2021 Annual review. Updated background with no changes to clinical\ncriteria. Updated reference.\n8/2022 Annual review. Added Child-Pugh classes for decompensated cirrhosis.\n8/2023 Annual review with no changes to coverage criteria. Updated\nreference.\n8/2024 Annual review with no changes to coverage criteria.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}